Ibrutinib

Anti-angiogenesis

MECHANISM OF ACTION

BRU-TKI

MECHANISM OF KIDNEY INJURY

CLINICAL KIDNEY SYNDROME

Extra-renal, Cardiotoxic, Hepatotoxic, HTN

CARDIOVASCULAR ADVERSE EFFECTS

LYTE ABNORMALITIES

RISK FACTORS

MITIGATION STRATEGIES

SUGGESTIONS

NOTES/COMMENTS

eGFR < 60 ml/min, no dose adjustment

PHARMACOKINETICS

Molecular Weight

440

Volume of Distribution

Vd: 683 L; Vdss/F: ~10,000 L

Plasma Protein Binding

97%

Metabolism

Bioavailability

Half-life elimination

4-6 hours

Time to peak

Excretion

80% Feces

Dialyzable?

REF:

PATHOLOGY SLIDES:

ENTRY UPDATES:

Raad Chowdhury

United States

Sep 25, 2022

PARTNERS WITH